

MASTER TRIAL LIST

MARCH 2025

SCHEMAS ARE INACTIVE



New or ReOpened Trials



No Trials Currently Available

JUST IN TIME TRIALS (JIT)

AML

ANAL

ALL

APL

BILIARY

BLADDER-UROTHELIAL

BRAIN

BREAST/ GYN

CANCER CONTROL /
SURVIVORSHIP

CLL

CML

COLON-RECTAL

ESOPHAGEAL - GASTRIC

HEAD & NECK

LYMPHOMA

MDS/MPN

MELANOMA

MERKEL

MOLECULAR STUDIES

MULTIPLE MYELOMA

NEUROENDOCRINE

NSCLC

PANCREATIC

PROSTATE

RADIATION TRIALS

RENAL CELL

SARCOMA

SMALL CELL LUNG CANCER

Updated 3.4.25

RADIATION LOCATIONS:

OSF Glen Oak - OSF main hospital

OSF Route 91 (attached to Illinois CancerCare)

SJMC - St Joseph Medical Center



JUST IN TIME (JIT) TRIALS

*Contact Disease Specific Navigator

Multi-Disease Site: Advanced/Metastatic Solid Tumors

EAY191- (Combomatch) E5

A Randomized Phase II Study of AMG 510 (Sotorasib) With or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

EAY191 - (Combomatch) N5

A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial

EAY191 (Combomatch) - S3

A Phase II Study of Paclitaxel + Ipatasertib In Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors)

ALL

EA9213

A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)

AL Amyloidosis

S2213

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients With Newly Diagnosed AL Amyloidosis

Biliary

EAY191 (ComboMatch) -A6

FOLFOX in Combination With Binimetinib as 2nd Line Therapy for Patients With Advanced Biliary Tract Cancers With MAPK Pathway Alterations: A ComboMATCH Treatment Trial

CLL

S1925

Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study

Gynecological

<u>GY026</u>	A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma <i>(temporarily closed for stage I-II for interim analysis)</i>
Genitourinary - Rare	
<u>A031702</u>	Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors <i>Enrolling cohorts: renal collecting duct, bladder plasmacytoid, sarcomatoid bladder, urethral carcinoma (which allows any histology urothelial, squamous, clear cell, or adenocarcinoma), and Bone only (which allows for any GU histology, except prostate).</i>
Head & Neck	
<u>A092205</u>	Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Platinum Refractory Disease
<u>EA3191</u>	A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
<u>EA3202</u>	A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
<u>EA3211</u>	Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma
<u>HN010</u>	A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naive, Unresectable HER2-Positive Salivary Gland Cancer
Melanoma	
<u>A091903</u>	A Randomized Phase II Trial of Adjuvant Nivolumab With or Without Cabozantinib in Patients With Resected Mucosal Melanoma
Multiple Myeloma	
<u>A062102</u>	Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecaptagene Vicleucel CAR-T in Multiple Myeloma Patients

SCHEMA

<p><u>EAA173</u></p> <p>SCHEMA</p>	<p>Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)</p>
<p style="text-align: center;">Neuroendocrine</p>	
<p><u>S2104</u></p>	<p>Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors</p>
<p style="text-align: center;">Pancreas</p>	
<p><u>A022106</u></p>	<p>Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)</p>
<p><u>S2104</u></p>	<p>Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors</p>
<p style="text-align: center;">Thyroid</p>	
<p><u>EA3231</u></p>	<p>A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em</p>



MASTER TRIAL LIST

MARCH 2025



AML

Navigator - Heather x3661

MM1YA-S01

SCHEMA

A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) to (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger With High-Risk (Adverse) Acute Myeloid Leukemia; **A MYELOMATCH Clinical Trial**



ILLINOIS
CANCERCARE, P.C.

Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

MARCH 2025



MENU

ANAL

Navigator - Carrie x3621



ILLINOIS
CANCERCARE, P.C.

Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

MARCH 2025

[MENU](#)

APL

Navigator - Heather x3661

There are no trials available at this time



MASTER TRIAL LIST

MARCH 2025



ACUTE LYMPHOBLASTIC LEUKEMIA

Navigator - Heather x3661

[EA9213 - JIT Trial](#)

A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)



MASTER TRIAL LIST

MARCH 2025



BILIARY

Navigator - Carrie x3621

<p>EAY191 (ComboMatch) -A3</p> <p>SCHEMA</p>	<p>Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial (<i>cohorts for pancreatic cancer and other RAS mutant tumors are temporarily closed</i>)</p>
<p>EAY191 (ComboMatch) -A6</p> <p>(JIT)</p>	<p>FOLFOX in Combination With Binimetinib as 2nd Line Therapy for Patients With Advanced Biliary Tract Cancers With MAPK Pathway Alterations: A ComboMATCH Treatment Trial</p>



MASTER TRIAL LIST

MARCH 2025



BLADDER / UROTHELIAL

Navigator - Carrie x3621

ADJUVANT / NEOADJUVANT

A032103

SCHEMA

An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer (MODERN)

METASTATIC

no trial available at this time



MASTER TRIAL LIST

MARCH 2025

MENU

BRAIN

Navigator - Carrie x3621

<p><u>A071702</u></p> <p>SCHEMA</p>	<p>Temporarily Suspended A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma</p>
<p><u>A072201</u></p> <p>SCHEMA</p>	<p>Temporarily Suspended Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients With Recurrent Glioblastoma</p>
<p><u>BN011</u></p> <p>SCHEMA</p>	<p>(RT at SJMC, Glen Oak) A Phase III Trial of Gleostine® (Lomustine)-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma</p>



BREAST

Navigator - Angie x3613

DCIS

No trials at this time

NEO/ADJUVANT TREATMENT

S1706*

Not Actively Screening - Contact Navigator - A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer (All biomarker subgroups eligible) | *JIT TRIAL - expect 1 week delay to consent pt

Neo/Adjuvant - HER2 Positive

A011801

The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib

Neo/Adjuvant - Hormone Receptor Positive / HER2 Negative

A012301

NEW! Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer

SCHEMA

BR007

(RT at Glen Oak, Rt 91, SJMC) Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer

SCHEMA

BR009

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)

SCHEMA

J2J-MC-JZLH / EMBER-

4

(Peoria, Bloomington, Galesburg, Pekin, Washington, Ottawa, Peru) A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence

SCHEMA







S2206

Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

SCHEMA

Neo/Adjuvant - Triple Negative

<u>A012103</u> SCHEMA	OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
<u>01-PS-001/ NeXT</u> SCHEMA	(sites TBD) Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)
<u>S2212 / SCARLET</u> SCHEMA	Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
METASTATIC TREATMENT	
Metastatic - HER2 Positive <i>(no trials at this time)</i>	
Metastatic - Hormone Receptor Positive / HER2 Negative	
<u>S1703</u>	Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
<u>S2007</u>	<u>Not Actively Screening - contact Navigator-</u> A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases
Metastatic - Triple Negative <i>(no trials at this time)</i>	
SURGERY / RADIATION ONLY	
<u>MA.39</u>	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer <i>(RT: Glen Oak)</i>
CANCER CONTROL (Breast only)	
<u>CC011</u> SCHEMA	Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial
<u>EAQ222CD</u> SCHEMA	COMING SOON! Effectiveness of Out-of-Pocket Cost COMMunication and Financial Navigation (CostCOM) in Cancer Patients
<u>S2013</u> SCHEMA	(Peoria, Bloomington, Galesburg, Pekin, Washington) Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study (I-CHECKIT) (Enrolling to Cohort 2 only: ICI-chemo regimens for NSCLC, SCLC, TNBC, and Gastroesophageal)
<u>URCC-18007</u>	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue- <i>at least 2 months out from surgery/tx/radiation</i>
<u>URCC 19185</u> SCHEMA	(Peoria, Bloomington, Canton, Galesburg, Ottawa, Pekin, Peru, Washington) Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)

<p><u>URCC 21038</u> </p>	<p>(Peoria, Bloomington, Galesburg, Pekin, Washington) Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting <i>(limited enrollment remaining for caucasian pts - contact CRC to confirm availability)</i></p>
<p><u>WF-1901</u> </p>	<p>Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)</p>
<p><u>WF-2202</u> </p>	<p>Optimizing Psychosocial Intervention for Breast Cancer-Related Sexual Morbidity:The Sexual Health and Intimacy Education (SHINE) Trial <i>(temporarily closing to non-hispanic white participants on 8.22.24)</i></p>
<p><u>WF2304-A172401 (COSMIC)</u> </p>	<p>Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics <i>(enrolling breast, colorectal, melanoma, NHL, NSCLC pts only)</i></p>
<p>GYNECOLOGICAL</p>	
<p>Navigator - Angie x3613</p>	
<p><u>NRG - GY023</u> </p>	<p>Temporarily Closed A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor (Durvalumab) MEDI4736 in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or (Durvalumab) MEDI4736 and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab</p>
<p><u>EAY191 (ComboMATCH) - A3</u> </p>	<p>Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial <i>(cohort for pancreatic cancer temporarily closed)</i></p>
<p><u>EAY191 (ComboMATCH) - N4</u></p>	<p><i>Molecular Analysis for combination Therapy Choice</i> (SUBSTUDY- N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers)</p>



CANCER CONTROL

SURVIVORSHIP

<u>CC011</u> SCHEMA	Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial
<u>EAQ211</u> SCHEMA	Social Genomic Mechanisms of Health Disparities Among Adolescent and Young Adult (AYA) Survivors of Hodgkin and Non-Hodgkin Lymphoma
<u>URCC-18007</u> SCHEMA	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - <i>at least 2 months out from surgery/tx/radiation</i>
<u>WF-1901</u> SCHEMA	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)
<u>WF-2202</u> SCHEMA	Optimizing Psychosocial Intervention for Breast Cancer-Related Sexual Morbidity: The Sexual Health and Intimacy Education (SHINE) Trial <i>(temporarily closing to non-hispanic white participants on 8.22.24)</i>
<u>WF2304-A172401 (COSMIC)</u> SCHEMA	Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics <i>(enrolling breast, colorectal, melanoma, NHL, NSCLC pts only)</i>

MULTI-DISEASE SITES

<u>EAQ202</u> SCHEMA	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials <i>(caucasian cohort is closed - currently enrolling only non-caucasian participants)</i>
<u>EAQ222CD</u> SCHEMA	COMING SOON! Effectiveness of Out-of-Pocket Cost COMMunication and Financial Navigation (CostCOM) in Cancer Patients
<u>S2013</u> SCHEMA	(Peoria, Bloomington, Galesburg, Pekin, Washington) Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study (I-CHECKIT) <i>(Enrolling to Cohort 2 only: ICI - chemo regimens for NSCLC, SCLC, TNBC, and Gastroesophageal)</i>
<u>URCC-18007</u>	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - <i>at least 2 months out from surgery/tx/radiation</i>
<u>URCC 19185</u> SCHEMA	(Peoria, Bloomington, Canton, Galesburg, Ottawa, Pekin, Peru, Washington) Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)
<u>URCC 21038</u> SCHEMA	(Peoria, Bloomington, Galesburg, Pekin, Washington) Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting <i>(limited enrollment remaining for caucasian pts - contact CRC to confirm availability)</i>
<u>URCC 22063</u> SCHEMA	Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia

<u>WF-1901</u> 	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)	
BREAST		
<u>CC011</u> 	Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial	
<u>WF-2202</u> 	Optimizing Psychosocial Intervention for Breast Cancer-Related Sexual Morbidity: The Sexual Health and Intimacy Education (SHINE) Trial <i>(temporarily closing to non-hispanic white participants on 8.22.24)</i>	
COLORECTAL		
<u>WF-1806</u> 	Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer: The M&M Study	
HEAD & NECK		
<u>CC013</u> 	NEW! Temporarily Closed (Credentialed at Glen Oak and Rt 91) A Randomized, Masked, Placebo Controlled, Phase II Trial Of Concurrent Chemoradiation With BMX-001 In Patients With Head And Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation	
LYMPHOMA		
<u>EAQ211</u> 	Social Genomic Mechanisms of Health Disparities Among Adolescent and Young Adult (AYA) Survivors of Hodgkin and Non-Hodgkin Lymphoma	
REGISTRY		
		*Contact Disease Specific Navigator
<u>PRECEDE</u>	The Pancreatic Cancer Early Detection Consortium	
<u>TP-CA-007 ARIES</u>	TEMPUS ARIES: A Biobank Registry Platform Study in Oncology <i>(currently enrolling KRAS+ CRC, NSCLC, and Pancreatic cancer pts)</i>	



MASTER TRIAL LIST

MARCH 2025



CLL

Navigator - Heather x3661

1st Line

<p><u>APG2575CG301</u></p> <p>SCHEMA</p>	<p>(Peoria, Bloomington, Galesburg, Pekin, Peru, Ottawa, Washtington) A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of LISAFTOCLAX (APG-2575) in Previously Treated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA Study) <i>*for 1st line tx - patients must be on initial frontline acalabrutinib for 1 year to be eligible</i></p>
<p><u>S1925-JIT</u></p>	<p>Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study</p>
<h3>2nd Line, 3rd Line, etc.</h3>	
<p><u>APG2575CG301</u></p> <p>SCHEMA</p>	<p>(Peoria, Bloomington, Galesburg, Pekin, Peru, Ottawa, Washtington) A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of LISAFTOCLAX (APG-2575) in Previously Treated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA Study)</p>



MASTER TRIAL LIST

MARCH 2025



CML

Navigator - Heather x3661

no trials at this time



MASTER TRIAL LIST

MARCH 2025



COLON / RECTAL

Navigator - Carrie x3621

Adjuvant

<p><u>C-14</u></p>	<p>(Peoria, Bloomington, Canton, Galesburg, Ottawa, Pekin, Peru, Washington) Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using A Circulating Tumor DNA Assay To Detect Minimal Residual Disease (CORRECT-MRD II)</p>
<p><u>GI008</u></p> <p>SCHEMA</p>	<p>Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease</p>
<p>CANCER CONTROL (Colorectal only)</p>	
<p><u>EAQ202</u></p> <p>SCHEMA</p>	<p>Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials (<i>caucasian cohort is closed - currently enrolling only <u>non</u>-caucasian participants</i>)</p>
<p><u>EAQ222CD</u></p> <p>SCHEMA</p>	<p>COMING SOON! Effectiveness of Out-of-Pocket Cost COMMunication and Financial Navigation (CostCOM) in Cancer Patients</p>
<p><u>TP-CA-007 ARIES</u></p>	<p>TEMPUS ARIES: A Biobank Registry Platform Study in Oncology (<i>currently enrolling KRAS+ CRC, NSCLC, and Pancreatic cancer pts</i>)</p>
<p><u>URCC-18007</u></p>	<p>Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - <i>at least 2 months out from surgery/tx/radiation</i></p>
<p><u>URCC 19185</u></p> <p>SCHEMA</p>	<p>(Peoria, Bloomington, Canton, Galesburg, Ottawa, Pekin, Peru, Washington) Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)</p>

<p><u>URCC 21038</u></p> <p></p>	<p>(Peoria, Bloomington, Galesburg, Pekin, Washington) Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting <i>(limited enrollment remaining for caucasian pts - contact CRC to confirm availability)</i></p>
<p><u>URCC 22063</u></p> <p></p>	<p>Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia</p>
<p><u>WF-1806</u></p> <p></p>	<p>Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer: The M&M Study</p>
<p><u>WF-1901</u></p> <p></p>	<p>Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)</p>
<p><u>WF2304-A172401</u> <u>(COSMIC)</u></p> <p></p>	<p>Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics <i>(enrolling breast, colorectal, melanoma, NHL, NSCLC pts only)</i></p>



MASTER TRIAL LIST

MARCH 2025



ESOPHAGEAL- GASTRIC

Navigator - Carrie x3621


<p>A022102</p> <p>SCHEMA</p>	<p>Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma</p>
<p>S2303</p> <p>SCHEMA</p>	<p>Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients With PD-L1 CPS \geq 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMMUNE)</p>

HEAD & NECK

Navigator - Ashton x3611

ADJUVANT/NEOADJUVANT

<u>EA3161</u>	Temporarily Closed (RT at Glen Oak) A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
<u>EA3191 - JIT</u>	A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
<u>HN009</u>	(RT at SJMC) Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m ²) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m ²) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) (accrual closed to p16+ oropharyngeal/unknown primary cohort)
<h3>METASTATIC</h3>	
<u>A092205-JIT</u>	Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Platinum Refractory Disease
<u>EA3202-JIT</u>	A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
<u>EA3211 - JIT</u>	Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma

<p><u>HN010 - JIT</u></p>	<p>A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naive, Unresectable HER2-Positive Salivary Gland Cancer</p>
<p><u>S2101</u></p> <p></p>	<p>Temporarily Closed Biomarker Stratified Cabozantinib (NSC#761968) and Nivolumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study</p>
<p><u>TP-CA-006 (PHOENIX)</u></p>	<p>A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Head & Neck Squamous Cell Carcinoma (HNSCC)</p>

LYMPHOMA

HL

No HL trials at this time

NHL

GO44145

SCHEMA

(Peoria, Bloomington, Galesburg, Ottawa, Pekin, Peru, Washington) | A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

M22-003

SCHEMA

(Peoria, Bloomington, Galesburg, Ottawa, Pekin, Peru, Washington) A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

S2308

SCHEMA

Randomized Phase III Study of Mosunetuzumab vs Rituximab for Low Tumor Burden Follicular Lymphoma



ILLINOIS
CANCERCARE, P.C.

Specializing in Cancer and Blood Disorders

MASTER TRIAL LIST

MARCH 2025



MENU

MDS/MPN

Navigator - Heather x3661

No trials at this time



MASTER TRIAL LIST

MARCH 2025



MELANOMA

Navigator - Carrie x3621

<p><u>A091903 - JIT Trial</u></p>	<p>A Randomized Phase II Trial of Adjuvant Nivolumab With or Without Cabozantinib in Patients With Resected Mucosal Melanoma</p>
<p><u>R3767-ONC-22122</u></p> <p>SCHEMA</p>	<p>(Peoria, Bloomington, Galesburg, Ottawa, Pekin, Peru, Washington) A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma.</p>
<p><u>S2101</u></p> <p>SCHEMA</p>	<p>Temporarily Closed Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study</p>



ILLINOIS
CANCERCARE, P.C.
Specializing in Cancer and Blood Disorders;

MASTER TRIAL LIST

MARCH 2025

[MENU](#)

MERKEL

Navigator - Carrie x3621

no trials at this time.

MASTER TRIAL LIST

MARCH 2025

MENU

MOLECULAR STUDIES

*Contact Disease Specific Navigator

EAY191 - COMBOMATCH	Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (<i>multiple substudies available</i>)
EAY191 (ComboMatch) -A3 SCHEMA	Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial (<i>cohorts for pancreatic cancer and other RAS mutant tumors are temporarily closed</i>)
EAY191 (ComboMatch) -A6	FOLFOX in Combination With Binimetinib as 2nd Line Therapy for Patients With Advanced Biliary Tract Cancers With MAPK Pathway Alterations: A ComboMATCH Treatment Trial
EAY191- (Combomatch) E5	A Randomized Phase II Study of AMG 510 (Sotorasib) With or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial
EAY191 (Combomatch) - N2	<i>Molecular Analysis for combination Therapy Choice</i> (SUBSTUDY- N2 : Phase II Trial of Fulvestrant and Binimetinib in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With A Frameshift or Nonsense Mutation or Genomic Deletion in NF1)
EAY191 (ComboMATCH) - N4	<i>Molecular Analysis for combination Therapy Choice</i> (SUBSTUDY- N4 : A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers)
EAY191 - (Combomatch) N5	A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial
EAY191 (Combomatch) - S3	A Phase II Study of Paclitaxel + Ipatasertib In Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors)
PRECEDE	The Pancreatic Cancer Early Detection Consortium
TP-CA-003 (Sculptor)	(Peoria, Blm, Canton, Gburg, Ottawa, Pekin, Peru, Washington) A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients with Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays (TEMPUS)

<u>TP-CA-006 (PHOENIX)</u>	A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Head & Neck Squamous Cell Carcinoma (HNSCC)
<u>TP-CA-007 ARIES</u>	TEMPUS ARIES: A Biobank Registry Platform Study in Oncology (<i>currently enrolling KRAS+ CRC, NSCLC, and Pancreatic cancer pts</i>)

MASTER TRIAL LIST

MARCH 2025



MULTIPLE MYELOMA

Navigator - Heather x3661

<p><u>A062102 - JIT</u> SCHEMA</p>	<p>Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecaptagene Vicleucel CAR-T in Multiple Myeloma Patients</p>
<p><u>EAA173 - JIT</u> SCHEMA</p>	<p>Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)</p>
<p><u>S2209</u> SCHEMA</p>	<p>A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance</p>

MASTER TRIAL LIST

MARCH 2025



NEUROENDOCRINE

Navigator - Carrie x3621

<u>A021804</u>	A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma
<u>S2104 - JIT Trial</u>	Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

NSCLC

Navigator - Ashton x3611

ADJUVANT / NEOADJUVANT

<p>A081801 SCHEMA</p>	<p>(Peoria, Bloomington, Pekin, Galesburg, Washington, Ottawa) Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)</p>
<p>LU008 SCHEMA</p>	<p>(RT at Glen Oak, SJMC, Rt 91) Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer</p>
<p>CTIU2317-A082304-S2402 SCHEMA</p>	<p>Perioperative Versus Adjuvant Systemic Therapy in Patients With Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG</p>

METASTATIC - 1st Line


<p>EA5182 SCHEMA</p>	<p>Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)</p>
<p>MK-3475A-F84 SCHEMA</p>	<p>A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK3475A) Versus Intravenous Pembrolizumab, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS ≥50%</p>
<p>SMT112-3003 (HARMONi-3)</p>	<p>COMING SOON! Phase 3 randomized, parallel-group, blinded, multiregional study comparing the efficacy and safety of ivonescimab or pembrolizumab, combined with carboplatin and paclitaxel or nab-paclitaxel for metastatic squamous NSCLC, or carboplatin plus pemetrexed chemotherapy for metastatic non-squamous NSCLC patients, who have not previously received systemic therapy for metastatic disease (HARMONi-3)</p>

METASTATIC - 2nd/3rd Line

<p>LUNGMAP</p>	<p>A Master Protocol To Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated NSCLC.</p> <p>S1900G (substudy) - A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer</p> <p>S1900J (substudy): A Phase II Study of Amivantamab SC (subcutaneous) in Participants with MET Amplification - Positive Stage IV or Recurrent NSCLC</p> <p>S1900K (substudy)- A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer</p>
--------------------------------	---

CANCER CONTROL (NSCLC Only)

<p>EAQ202 SCHEMA</p>	<p>Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials (<i>caucasian cohort is closed - currently enrolling only non-caucasian participants</i>)</p>
<p>EAQ222CD SCHEMA</p>	<p>COMING SOON! Effectiveness of Out-of-Pocket Cost COMMunication and Financial Navigation (CostCOM) in Cancer Patients</p>
<p>S2013 SCHEMA</p>	<p>(Peoria, Bloomington, Galesburg, Pekin, Washington) Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study (I-CHECKIT) (<i>Enrolling to Cohort 2 only: ICI - chemo regimens for NSCLC, SCLC, TNBC, and Gastroesophageal</i>)</p>

<p><u>TP-CA-007 ARIES</u></p>	<p>TEMPUS ARIES: A Biobank Registry Platform Study in Oncology (<i>currently enrolling KRAS+ CRC, NSCLC, and Pancreatic cancer pts</i>)</p>
<p><u>URCC-18007</u></p>	<p>Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - <i>at least 2 months out from surgery/tx/radiation</i></p>
<p><u>URCC 19185</u> </p>	<p>(Peoria, Bloomington, Canton, Galesburg, Ottawa, Pekin, Peru, Washington) Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)</p>
<p><u>URCC 21038</u> </p>	<p>(Peoria, Bloomington, Galesburg, Pekin, Washington) Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting (<i>limited enrollment remaining for caucasian pts - contact CRC to confirm availability</i>)</p>
<p><u>URCC 22063</u> </p>	<p>Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia</p>
<p><u>WF-1901</u> </p>	<p>Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)</p>
<p><u>WF2304-A172401 (COSMIC)</u> </p>	<p>Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics (<i>enrolling breast, colorectal, melanoma, NHL, NSCLC pts only</i>)</p>



MASTER TRIAL LIST

MARCH 2025



PANCREATIC

Navigator - Carrie x3621

<p><u>A022106 - JIT</u></p>	<p>Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)</p>
<p><u>EA2192</u></p> <p>SCHEMA</p>	<p>A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation (APOLLO)</p>
<p><u>EAY191 (ComboMATCH) - A3</u></p> <p>SCHEMA</p>	<p>Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial <i>(cohorts for pancreatic cancer and other RAS mutant tumors are temporarily closed)</i></p>
<p><u>S2001</u></p> <p>SCHEMA</p>	<p>Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations</p>
<p><u>S2104 - JIT Trial</u></p>	<p>Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors</p>
<p><u>TP-CA-007 ARIES</u></p>	<p>TEMPUS ARIES: A Biobank Registry Platform Study in Oncology <i>(currently enrolling KRAS+ CRC, NSCLC, and Pancreatic cancer pts)</i></p>

PROSTATE

Navigator - Carrie x3621

ADJUVANT

<p><u>GU008</u></p> <p>SCHEMA</p>	<p>(RT at Glen Oak) Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE): <i>Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy</i></p>
<p><u>GU009</u></p> <p>SCHEMA</p>	<p>(RT at Glen Oak and Rt 91) Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*) (<i>intensification cohort (groups 3 and 4) closed to accrual</i>)</p>
<p><u>GU010</u></p> <p>SCHEMA</p>	<p>(RT at Glen Oak) Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE) (<i>intensification cohort (groups 3 and 4) closed to accrual</i>)</p>
<p><u>GU013</u></p> <p>SCHEMA</p>	<p>(RT at Glen Oak) The Phase III 'High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer</p>
<p>METASTATIC</p>	
<p><u>A032102</u></p> <p>SCHEMA</p>	<p>PREcision Diagnostics in Prostate Cancer Treatment (PREDICT)</p>
<p>MK5684-004</p>	<p>(Peoria, Bloomington, Galesburg, Pekin, Peru, Ottawa, Washington) A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA)</p>

S2312

SCHEMA

A Phase III Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature

MASTER TRIAL LIST

MARCH 2025



RENAL CELL

Navigator - Carrie x3621

<p><u>EA8211</u></p> <p>SCHEMA</p>	<p>(RT at Rt 91, Glen Oak) Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR)</p>
<p><u>S2200</u></p> <p>SCHEMA</p>	<p>A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)</p>
<p><u>A032201</u></p> <p>SCHEMA</p>	<p>NEW! Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE</p>

MASTER TRIAL LIST

MARCH 2025

MENU

RADIATION TRIALS

Navigator - Jessica x3615

BRAIN	
<u>BN011</u>	(RT at SJMC, Glen Oak) A Phase III Trial of Gleostine® (Lomustine)-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma
BRAIN METS	
<u>BN010</u>	(RT at Glen Oak) A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma (currently enrolling to phase II non-surgical cohort)
<u>BN012</u>	(RT credentialing pending) A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
<u>CCTG CE.7</u>	(Glen Oak)- A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases
<u>WF-2201</u>	(Glen Oak; Pending at Rt 91) - Hypofractionated Radiotherapy vs Single Fraction Radiosurgery For Brain Metastasis Patients On Immunotherapy (HYPOGRYPHE)
BREAST	
<u>BR007</u>	(Glen Oak, Rt 91, SJMC) Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
<u>MA.39</u>	(Glen Oak) Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
HEAD & NECK	
<u>EA3161</u>	Temporarily Closed (Glen Oak) A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC

<u>EA3211 - JIT</u>	Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma
<u>HN009</u> <small>SCHEMA</small>	(RT at SJMC) Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m ²) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m ²) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) (<i>accrual closed to p16+ oropharyngeal/unknown primary cohort</i>)
NSCLC	
<u>LU008</u> <small>SCHEMA</small>	(RT at Glen Oak, SJMC, Rt 91) Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
PROSTATE	
<u>GU008</u> <small>SCHEMA</small>	(RT at Glen Oak) Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE): <i>Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy</i>
<u>GU009</u> <small>SCHEMA</small>	(RT at Glen Oak, Rt 91) Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*) (<i>intensification cohort (groups 3 and 4) closed to accrual</i>)
<u>GU010</u> <small>SCHEMA</small>	(RT at Glen Oak) Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE) (<i>intensification cohort (groups 3 and 4) closed to accrual</i>)
<u>GU013</u> <small>SCHEMA</small>	(RT at Glen Oak) The Phase III 'High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer
RENAL	
<u>EA8211</u> <small>SCHEMA</small>	(RT at Rt 91, Glen Oak) Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR)
SCLC	

<p><u>NRG CC009</u></p> <p><u>SCHEMA</u></p>	<p>(Glen Oak) - Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer</p>
<p><u>S1827</u></p>	<p>(Glen Oak, SJMC) A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer</p>



MASTER TRIAL LIST

MARCH 2025



SARCOMA

Navigator - Carrie x3621

EA7222

SCHEMA

A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

SMALL CELL LUNG CANCER

Navigator - Ashton x3611

<p><u>CA245-0001</u></p> <p>SCHEMA</p>	<p>NEW! (Peoria, Bloomington, Galesburg, Ottawa, Pekin, Peru, Washington) A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).</p>
<p><u>NRG CC009</u></p> <p>SCHEMA</p>	<p>(RT at Glen Oak) - Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer</p>
<p><u>S1827</u></p>	<p>(RT at Glen Oak, SJMC) A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer</p>
<p><u>TP-CA-003 (Sculptor)</u></p>	<p>(Peoria, Blm, Canton, Gburg, Ottawa, Pekin, Peru, Washington) A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients with Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays (TEMPUS)</p>